The OCIAD1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the Raji B lymphocyte line, featuring targeted disruption of the OCIAD1 gene to create a loss-of-function model for studying mitochondrial complex I biology. This polyclonal format encompasses a heterogeneous mix of edited alleles, circumventing clonal selection artifacts and maintaining the population-level phenotypic diversity that is essential for robust metabolic and oncogenic signaling analyses. By avoiding monoclonal derivation, the cells provide a more physiologically relevant substrate for investigating OCIAD1-dependent processes in a lymphoma background.
The Raji cell line is a human EBV-positive Burkitt’s lymphoma B lymphocyte model extensively used in B-cell biology, immunology, and oncology research. Originating from a patient with Burkitt’s lymphoma, Raji cells display characteristic features of aggressive B-cell malignancies, including rapid proliferation, suspension growth, and expression of B-cell markers. Their well-characterized genetic landscape and stable in vitro culture properties make them an ideal host for engineered knockout studies, especially for exploring mitochondrial adaptations in transformed B cells.
OCIAD1 encodes a mitochondrial inner membrane protein that acts as a scaffold for the assembly and stability of NADH dehydrogenase (complex I), directly interacting with assembly factors such as NDUFAF4 and core subunits including NDUFV1 and NDUFS1. Expression of OCIAD1 is driven by upstream transcriptional regulators LEF1, STAT3, and c-MYC, integrating signals from oncogenic pathways. Downstream, OCIAD1 activity modulates oxidative phosphorylation, ATP synthesis, and mitochondrial ROS production, while also influencing cell cycle progression through CDK inhibitors. These functions position OCIAD1 at a nexus between PI3K/AKT/mTOR signaling and mitochondrial electron transport, critical for balancing energy metabolism and proliferation.
In Raji lymphoma cells, OCIAD1 knockout is anticipated to impair complex I activity, leading to compromised mitochondrial respiration and a shift towards alternative metabolic programs. Given the reliance of many B-cell malignancies on oxidative phosphorylation, disrupting OCIAD1 may expose vulnerabilities in mitochondrial energy homeostasis that are relevant to Burkitt’s lymphoma pathogenesis. This model enables dissection of how OCIAD1-dependent regulation of complex I affects B-cell activation, survival, and oncogenic growth, particularly under conditions that challenge bioenergetic capacity. Furthermore, it provides a platform for evaluating synthetic lethal interactions with inhibitors of PI3K/AKT or compensatory metabolic pathways.
Researchers can employ these polyclonal knockout cells to investigate mitochondrial dysfunction in B-cell lymphoma through assays such as Seahorse metabolic flux analysis, ATP level quantification, and flow cytometric measurement of mitochondrial mass and ROS production. Compatible with RNA-seq for mapping OCIAD1-dependent gene networks and proliferation assays to evaluate cell cycle effects, these cells are valuable for drug screening campaigns targeting mitochondrial complex I or oxidative phosphorylation in hematopoietic cancers, and for validating OCIAD1 as a therapeutic vulnerability. For further information, please contact Ascent Research.
